Cargando…

Immunotherapy using PD-1/PDL-1 inhibitors in metastatic triple-negative breast cancer: A systematic review

Breast cancer is the most commonly diagnosed cancer in women and is one of the leading causes of death from cancer in women worldwide. Despite the significant benefits of using conventional chemotherapy in the treatment of breast cancer, one of its subtypes, the triple-negative breast cancer, is sti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tavares, Dione Fernandes, Chaves Ribeiro, Victoria, Andrade, Marco Antônio Vieira, Moreira Cardoso-Júnior, Laércio, Rhangel Gomes Teixeira, Thiago, Ramos Varrone, Gabriela, Lopes Britto, Renata
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	PAGEPress Publications, Pavia, Italy 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8678626/ https://www.ncbi.nlm.nih.gov/pubmed/35003528 http://dx.doi.org/10.4081/oncol.2021.497

Ejemplares similares

Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy
por: Makuku, Rangarirai, et al.
Publicado: (2021)

Immunotherapy for Soft Tissue Sarcomas: Anti-PD1/PDL1 and Beyond
por: Fazel, Mina, et al.
Publicado: (2023)

Immunotherapy of Ovarian Cancer with Particular Emphasis on the PD-1/PDL-1 as Target Points
por: Świderska, Janina, et al.
Publicado: (2021)

Identification of PDL1-Related Biomarkers to Select Lung Adenocarcinoma Patients for PD1/PDL1 Inhibitors
por: Wu, Yanping, et al.
Publicado: (2020)

Management and prediction of immune-related adverse events for PD1/PDL-1 immunotherapy in colorectal cancer
por: Sun, Liting, et al.
Publicado: (2023)

Combined immunotherapy with anti-PDL-1/PD-1 and anti-CD4 antibodies cures syngeneic disseminated neuroblastoma
por: Rigo, Valentina, et al.
Publicado: (2017)

PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy
por: Sponaas, Anne-Marit, et al.
Publicado: (2015)

Trends in the Research Into Immune Checkpoint Blockade by Anti-PD1/PDL1 Antibodies in Cancer Immunotherapy: A Bibliometric Study
por: Sun, Yiting, et al.
Publicado: (2021)

Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis
por: Liu, Yanhao, et al.
Publicado: (2022)

Anlotinib Benefits the αPDL1 Immunotherapy by Activating ROS/JNK/AP-1 Pathway to Upregulate PDL1 Expression in Colorectal Cancer
por: Luo, Bixian, et al.
Publicado: (2022)

PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer
por: Stenehjem, David D, et al.
Publicado: (2018)

Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors
por: Lei, Qingyang, et al.
Publicado: (2020)

PD-1/PDL-1 Inhibitors and Cardiotoxicity; Molecular, Etiological and Management Outlines
por: Safi, Mohammed, et al.
Publicado: (2020)

Engineered extracellular vesicles for concurrent Anti-PDL1 immunotherapy and chemotherapy
por: Chen, Yundi, et al.
Publicado: (2021)

Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy
por: Weidhaas, Joanne, et al.
Publicado: (2022)

Machine-Learning Guided Discovery of Bioactive Inhibitors of PD1-PDL1 Interaction
por: Patil, Sachin P., et al.
Publicado: (2022)

Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma
por: Ameli, Fereshteh, et al.
Publicado: (2022)

Different Triple-Negative Breast Cancer Tumor Cell Lysates (TCLs) Induce Discrepant Anti-Tumor Immunity by PD1/PDL-1 Interaction
por: Dong, Bohan, et al.
Publicado: (2019)

Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types
por: Martin‐Romano, Patricia, et al.
Publicado: (2020)

Circulating Low Density Neutrophils Are Associated with Resistance to First Line Anti-PD1/PDL1 Immunotherapy in Non-Small Cell Lung Cancer
por: Arasanz, Hugo, et al.
Publicado: (2022)

Prognostic Value of BRAF, Programmed Cell Death 1 (PD1), and PD Ligand 1 (PDL1) Protein Expression in Colon Adenocarcinoma
por: Ibrahiem, Afaf T., et al.
Publicado: (2023)

Identification and Validation of a PD-L1 Binding Peptide for Determination of PDL1 Expression in Tumors
por: Caldwell, Charles, et al.
Publicado: (2017)

Smad7 Controls Immunoregulatory PDL2/1-PD1 Signaling in Intestinal Inflammation and Autoimmunity
por: Garo, Lucien P., et al.
Publicado: (2019)

The Prognostic Significance of PD1 and PDL1 Gene Expression in Lung Cancer: A Meta-Analysis
por: Chang, Chih-Hao, et al.
Publicado: (2021)

Integration of cancer stemness and neoantigen load to predict responsiveness to anti-PD1/PDL1 therapy
por: Luo, Kunpeng, et al.
Publicado: (2022)

Navigating through the PD-1/PDL-1 Landscape: A Systematic Review and Meta-Analysis of Clinical Outcomes in Hepatocellular Carcinoma and Their Influence on Immunotherapy and Tumor Microenvironment
por: Ailia, Muhammad Joan, et al.
Publicado: (2023)

Anion binding properties of a hollow PdL-cage
por: Timmer, Brian J. J., et al.
Publicado: (2021)

Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer
por: Yang, Tinglin, et al.
Publicado: (2023)

Immune modulation through targeting PD-1/PDL-1 signaling pathway for the treatment of osteosarcoma lung metastastasis
por: Dhupkar, Pooja M, et al.
Publicado: (2015)

TILs and Anti-PD1 Therapy: An Alternative Combination Therapy for PDL1 Negative Metastatic Cervical Cancer
por: Yin, Huanhuan, et al.
Publicado: (2020)

Survival and Pulmonary Injury After Neonatal Sepsis: PD1/PDL1's Contributions to Mouse and Human Immunopathology
por: Fallon, Eleanor A., et al.
Publicado: (2021)

Immune-Omics Networks of CD27, PD1, and PDL1 in Non-Small Cell Lung Cancer
por: Ye, Qing, et al.
Publicado: (2021)

Idiopathic CD4 T Cell Lymphocytopenia: A Case of Overexpression of PD-1/PDL-1 and CTLA-4
por: Kumar, Gaurav, et al.
Publicado: (2021)

Adjuvant Therapy With PD1/PDL1 Inhibitors for Human Cancers: A Systematic Review and Meta-Analysis
por: Jin, Yao, et al.
Publicado: (2022)

Is a Triggering Role or a Causative Role of PD-1/PDL-1 Inhibitors in the Development of Paraneoplastic Dermatomyositis?
por: Starace, Michela, et al.
Publicado: (2022)

Serum sPD1 and sPDL1 as Biomarkers for Evaluating the Immune State of Lung Adenocarcinoma Patients
por: Wu, Yumin, et al.
Publicado: (2022)

The effect of Wnt/β-catenin signaling on PD-1/PDL-1 axis in HPV-related cervical cancer
por: AGHBASH, PARISA SHIRI, et al.
Publicado: (2023)

MUC1-induced immunosuppression in colon cancer can be reversed by blocking the PD1/PDL1 signaling pathway
por: Zhang, Yinghui, et al.
Publicado: (2020)

PDL1 expression and its correlation with outcomes in non-metastatic triple-negative breast cancer (TNBC)
por: Ghosh, Joydeep, et al.
Publicado: (2021)

CSF1/CSF1R Axis Blockade Limits Mesothelioma and Enhances Efficiency of Anti-PDL1 Immunotherapy
por: Magkouta, Sophia Fotiou, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_eanfav8kgaigrt0hhkm0rt57bu